✦ LIBER ✦

Percutaneous intervention for unprotected left main disease prior to explantation of a left ventricular assist device

✍ Scribed by Samuel M. Butman; Karen Jamison; Marvin Slepian; Nancy Edling; Francisco Arabia; Jack G. Copeland

Publisher: John Wiley and Sons
Year: 2003
Tongue: English
Weight: 166 KB
Volume: 59
Category: Article
ISSN: 1522-1946
DOI: 10.1002/ccd.10540

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Results of percutaneous drug-eluting ste

Results of percutaneous drug-eluting stent implantation for unprotected left main coronary disease according to left ventricular systolic function

✍ Mario Bollati; Argyrios Gerasimou; Dario Sillano; Giuseppe Biondi-Zoccai; Paolo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 620 KB

Early and long-term results of percutane

Early and long-term results of percutaneous coronary intervention for unprotected left main trifurcation disease

✍ Imad Sheiban; Argyrios Gerasimou; Mario Bollati; Giuseppe Biondi-Zoccai; Filippo 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 2 views

Prevalence of unfavorable angiographic c

Prevalence of unfavorable angiographic characteristics for percutaneous intervention in patients with unprotected left main coronary artery disease

✍ Michael Ragosta; Sandra Dee; Ian J. Sarembock; Lewis C. Lipson; Lawrence W. Gimp 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 2 views

Economic outcomes of percutaneous corona

Economic outcomes of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with left main or three-vessel coronary artery disease: One-year results from the SYNTAX trial

✍ David J. Cohen; Tara A. Lavelle; Ben Van Hout; Haiyan Li; Yang Lei; Katherine Ro 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 287 KB 👁 2 views

## Abstract Objectives: To evaluate the cost‐effectiveness of alternative approaches to revascularization for patients with three‐vessel or left main coronary artery disease (CAD). Background: Previous studies have demonstrated that, despite higher initial costs, long‐term costs with bypass surgery